Firm Profile

Ha Kung WongHa Kung WongPartner, New York

Professional Experience

Ha Kung Wong practices general intellectual property law with an emphasis on complex patent and trade secret litigation in pharmaceuticals, biologics and chemistry. Cases Mr. Wong has litigated include those related to proton pump inhibitors, anti-epileptic drugs, anti-tussives and other pharmaceuticals. Mr. Wong also has extensive experience with intellectual property counseling, pre-suit investigations, licensing and due diligence.

Mr. Wong currently is the Chair of the Recruiting Committee, serves as faculty for NITA (the National Institute of Trial Advocacy) and Lawline, and has been named a "Furthered 40" by Lawline for his contributions.

Awards and Recognition

Ha Kung Wong is listed in Legal 500 2008 and 2009 for Patent litigation: full coverage. Mr. Wong is also listed as a Rising Star in Intellectual Property Litigation in the 2012-2014 issues of Super Lawyers: New York Metro Edition.

What Others Say:


  • [as someone who has] “an eye for detail” and “goes the extra mile” (Legal 500 2008) 
     

For information on the selection process, see:

Legal 500
Super Lawyers

Education

J.D., cum laude, Notre Dame Law School, 1999
B.S., Chemistry, High Distinction, B.S. Biochemistry, University of Illinois Urbana-Champaign, 1996

Bar Admissions

State of New York, 2000; U.S. District Courts for the Southern and Eastern Districts of New York, 2001

Professional Activities

American Bar Association; New York Bar Association; New York Patent Law Association; American Chemical Society; New York Intellectual Property Law Association

Additional Publications

While in law school, Mr. Wong served as Managing Editor for the Journal of Legislation and published, "The Extra in Extradition: Washington v. Pang's Impact on Extraditee Standing and Implicit Waiver," 24 J.Legis 111 (1998).

Representative Matters

  • AstraZeneca against Andrx, Genpharm, Dr. Reddy and Schwartz Pharma on patents relating to omeprazole and its formulations.
  • Bristol-Myers Squibb against The Regents of the University of Michigan and Repligen Corp. and ZymoGenetics on patents relating to synthetic fusion proteins for regulating the immune system.
  • UCB against Mylan, Dr. Reddy, Sandoz and Cobalt on patents relating to levetiracetam, a leading epilepsy medicine.
  • GlaxoSmithKline against Barr Pharmaceuticals on patents relating to dutasteride, a leading BPH drug.
  • UCB and Celltech against KV Pharmaceutical on patents relating to methylphenidate hydrochloride, an ADHD medicine.

Representative Cases

UCB Societe Anonyme & UCB Pharma Inc. v. Mylan Laboratories, Inc. et al.
N.D. Ga. (2006)
In re Omeprazole Patent Litigation
S.D.N.Y. (2002)

EVENTS

29th Annual Intellectual Property Law Conference
American Bar Association
Fitzpatrick partner Ha Kung Wong spoke at the 29th Annual Intellectual Property Law Conference
April 2-4, 2014
Biosimilars IP Counsel Exchange
Momentum Event Group
Fitzpatrick sponsored the Biosimilars IP Counsel Exchange
January 23, 2014
America Invents Act: The Significant Changes for Patent Prosecutors and Litigators
Lawline.com
October 21, 2011
21st Forum on Biotech Patenting
C5
October 5-6, 2011
2nd Annual Conference on Biosimilars
American Conference Institute
Fitzpatrick partners Raymond Mandra and Ha Kung Wong spoke at ACI's 2nd Annual Conference on Biosimilars
June 7-8, 2011
3rd Annual Pre-Litigation Strategy, Analysis and Preparation for Paragraph IV Disputes
The Center for Business Intelligence
October 18- 19, 2010
Assessing Small Molecule IP: Exclusivities & the Hatch-Waxman Act
lawline.com
September 15, 2010
5th Annual Pharmaceutical & Biotech Patent Litigation Strategies Conference
IQPC
Partners Scott K. Reed and Ha Kung Wong to speak at Biotech Conference in London
May 24-26th, 2010
Highlighting In-Depth Interference Practices, Patent Life Cycle Management and Litigation Tactics
IQPC's 2nd Annual Patent Strategies for the Pharma, Biotech and Medical Device Industries
July 15-16, 2008

PUBLICATIONS

Property rights: a brave new world for patent owners
International Law Office
July 2014
Patent term adjustment after Novartis v Lee
Managing Intellectual Property
April 2014
Uncertainty and unsatisfactory incentives
January 2014
Patent Claim Construction
Practical Law Company
June 2013
Impact of America Invents Act on Litigation Stays Pending USPTO Proceedings
New York Law Journal
June 2013
A Shifting Landscape in Patent False Marking: Effects of Recent Legal Changes
Financier Worldwide Magazine
October 2012
Strategic Patent Protection in the “New World” after the America Invents Act
China Intellectual Property Magazine
September 10, 2012
AIA & Paragraph IV Litigation: What’s Next?
LMG Life Sciences
May 2012
Conducting an IP Audit When Laws Change
New York Law Journal
May 9, 2012
Trade Secret Law Reform: Could an Amended Economic Espionage Act Overcome Inconsistencies in the Current State Law System?
Bloomberg Law Reports: Intellectual Property
January 2012
Preparing for Uncertainties in Biosimilars Litigation
Financier Worldwide
January 2011
Recent legislation impacts development of biologics
Financier Worldwide
November 2010
Obvious to Try? The Slippery Slope of Biotechnology
Bloomberg Law Reports Intellectual Property
May 10, 2010
Combine and conquer: handling biotech combination inventions in the wake of KSR
Nature Biotech
May 2009

IN THE NEWS

Twenty Fitzpatrick Partners Named As Top Intellectual Property Litigators
Super Lawyers: New York Metro Edition & Super Lawyers: Washington, D.C. Edition
September 2014
Nineteen Fitzpatrick Partners Named As Top Intellectual Property Litigators
Super Lawyers: New York Metro Edition & Super Lawyers: Washington, D.C. Edition
September 2013
Eleven Fitzpatrick Partners Named As Top New York Intellectual Property Litigators
Super Lawyers: New York Metro Edition
September 2012

PRESS RELEASES

New Partners named in January 2008
January 2, 2008